Holen Sie sich die Stockscreener-App
138.99
2.18%
-3.10
Handel nachbörslich:
141.21
2.22
+1.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration - Yahoo Finance
Sumitomo Mitsui Trust Group Reduces Gilead Sciences Stake - National Today
Greenup Street Wealth Management Boosts Gilead Sciences Stake - National Today
Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Massachusetts Financial Firm Boosts Gilead Sciences Holdings - National Today
Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area - CSRwire
Gilead Sciences (GILD) to acquire Tubulis for $5B to strengthen oncology pipeline - MSN
Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy? - simplywall.st
Ritholtz Wealth Management Boosts Gilead Sciences Stake - National Today
Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Taxation With Representation: Goodwin, CMS, Wilson Sonsini - Law360
AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00 - MarketBeat
Gilead projects $107M Q1 earnings headwind due to recent R&D deals - MSN
Cantor Fitzgerald Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $115.00 - MarketBeat
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
Tempus AI stock rises on Gilead collaboration deal - Investing.com
Spirepoint Private Client LLC Has $9.37 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Tempus AI stock rises on Gilead collaboration deal By Investing.com - Investing.com South Africa
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders - Yahoo Finance
Rx Rundown: Gilead Sciences, Jeito Capital, Neurocrine Biosciences and more - Medical Marketing and Media
Why Is Tempus AI Stock Gaining Friday?Tempus AI (NASDAQ:TEM) - Benzinga
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline - Yahoo Finance
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Tempus AI expands collaboration with Gilead Sciences By Investing.com - Investing.com Australia
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Benzinga
Gilead Expands Oncology Pipeline With $5B Tubulis Deal - Yahoo Finance
Focus on HIV therapies propels Gilead Sciences stock consolidation amid mixed technical momentum - Traders Union
Gilead Sciences Sees Institutional Investment Boost - National Today
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead price target raised to $155 from $152 at Truist - Yahoo Finance
Tempus AI expands collaboration with Gilead Sciences - Investing.com
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Yahoo Finance
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise - Business Wire
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com India
OFI Invest Asset Management Acquires 470,804 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
MH & Associates Securities Management Corp ADV Invests $4.57 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
8,451 Shares in Gilead Sciences, Inc. $GILD Bought by Jackson Square Capital LLC - MarketBeat
Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - AOL.com
Germany: Gilead significantly expanding ADC capabilities with agreement to acquire Tubulis for up to US$5bn - Investors in Healthcare
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Gilead to pay up to $5bn for antibody-drug conjugates push - Life Sciences Intellectual Property Review
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts - Yahoo Finance
Gilead's Commitment to Bridging the Unmet HIV Treatment Gap - Gilead Sciences
Gilead Sciences Inc. stock rises Wednesday, still underperforms market - MarketWatch
Gilead to Buy Cancer Biotech Tubulis in $5B Deal - marketscreener.com
Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
With 3 quick buyouts, Gilead leans into its latest transformation - BioPharma Dive
Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Dr - GuruFocus
Gilead takes another big swing at expanding beyond HIV - Endpoints News
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities - BioSpace
Truist raises Gilead Sciences stock price target on M&A activity - Investing.com
TD Cowen reiterates Buy on Gilead stock after recent acquisitions - Investing.com
BMO reiterates Gilead Sciences stock rating on Tubulis acquisition - Investing.com
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $165 to $175 - Moomoo
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Cantor Fitzgerald reiterates Gilead Sciences stock rating on Yeztugo beat - Investing.com
Gilead Sciences Is Doubling Down On Acquisitions (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating - TipRanks
Sivik Global Healthcare LLC Buys Shares of 25,000 Gilead Sciences, Inc. $GILD - MarketBeat
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $174 - Moomoo
Oppenheimer reiterates Gilead stock rating on acquisition strategy - Investing.com
Gilead strengthens ADC capabilities with $5bn Tubulis acquisition - European Pharmaceutical Review
0.21%
1.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):